Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
<iframe src="https://statesidedaily.com/embed/cluster/733115f573fa6ca9dcb29eb25a33f427d4915e55" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Goldman-Backed Biotech Attovia Raises $289 Million in US IPO"></iframe>